Literature DB >> 12972517

Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness.

Monika K Krzyzanowska1, Jane C Weeks, Craig C Earle.   

Abstract

PURPOSE: To evaluate the use and effectiveness of cancer-directed therapy in elderly patients with locally advanced pancreatic cancer (LAPC).
METHODS: We used the linked Surveillance, Epidemiology, and End Results Medicare database to perform a retrospective cohort study in 1,696 patients diagnosed with LAPC between 1991 and 1996. We calculated cancer-directed treatment use rates, then used logistic regression to identify patient and health system factors that were associated with receipt of treatment. Effectiveness of treatment was estimated using Cox proportional hazards models and propensity score methods.
RESULTS: In our cohort, 44% of patients received some form of cancer-directed therapy (24% radiation with concurrent chemotherapy, 13% radiation alone, and 7% chemotherapy alone). Older age, lower socioeconomic status, presence of comorbid illness, no care in a teaching hospital, and residence in the western United States were associated with a lower likelihood of receiving treatment (P </=.05). Among those treated, younger age and certain geographic locations were the only predictors of receiving combined-modality therapy. The adjusted hazard ratio for death associated with any treatment in the Cox model was 0.53 (P <.0001). Effectiveness estimates obtained using propensity score methods were similar.
CONCLUSION: This analysis supports the effectiveness of cancer-directed treatment in elderly patients with LAPC, but use is low. Receipt of treatment is strongly correlated with non-disease-related factors, especially sociodemographic characteristics, indicating possible disparities in access to care.

Entities:  

Mesh:

Year:  2003        PMID: 12972517     DOI: 10.1200/JCO.2003.03.007

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Pancreatic cancer in the general population: Improvements in survival over the last decade.

Authors:  Taylor S Riall; William H Nealon; James S Goodwin; Dong Zhang; Yong-Fang Kuo; Courtney M Townsend; Jean L Freeman
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

Review 2.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 3.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

4.  Underutilization of surgical resection in patients with localized pancreatic cancer.

Authors:  Taylor S Riall; Keith D Lillemoe
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

Review 5.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 6.  Update on the Management of Pancreatic Cancer in Older Adults.

Authors:  Shin Yin Lee; Moussa Sissoko; Kevan L Hartshorn
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

Review 7.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  National disparities in minimally invasive surgery for pancreatic tumors.

Authors:  Emmanuel Gabriel; Pragatheeshwar Thirunavukarasu; Kristopher Attwood; Steven J Nurkin
Journal:  Surg Endosc       Date:  2016-07-13       Impact factor: 4.584

9.  Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?

Authors:  Andrew P Loehrer; David C Chang; Matthew M Hutter; Zirui Song; Keith D Lillemoe; Andrew L Warshaw; Cristina R Ferrone
Journal:  J Am Coll Surg       Date:  2015-10-09       Impact factor: 6.113

10.  Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Authors:  Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.